Delayed Patents May Obtain Additional Patent Term Under District Court Ruling In Wyeth.
On September 30, 2008, the U.S. District Court for the District of Columbia issued a decision that changes how the U.S. Patent and Trademark Office (PTO) calculates a patent term adjustment under 35 U.S.C. s. 154. Wyeth v. Dudas, No. 07-1492 (D.D.C. 2008). Under current law, s....

IT's not in top 10 cos filing patents.
Byline: Sobha Menon NEW DELHI: It may be the IT industry that's spearheaded India's efforts to be recognised as a knowledge power. But if you're looking for intellectual property created, it's the biosciences, biotechnology, pharmaceuticals and chemicals industries that are quitely filing away for patents. ...

All rights reserved: how the gene-patenting race is affecting science.
Since the National Institutes of Health first filed for patients on thousands of fragments of human genes in 1992, a sense of unease has permeated much of the international community of human geneticists. Perhaps it is just the disquiet that comes with sudden change and its unknown consequences -...

Finding the right tool for the job: adequate protection for research tool patents in a global market?
I. PATENT LAWS IN THE UNITED STATES II. PROCESS PATENTS AMENDMENT ACT--HISTORICAL PERSPECTIVE III. BIOPHARMACEUTICALS: THE SCIENCE AND THE INDUSTRY A. Biotech 101-A Basic Primer on the Relevant Science B. The Focus of Biotechnology in the "Post-Genomic" Era C. What is a "Research Tool"? D. The Marriage of the...

Organisms and manufactures: on the history of plant inventions.
[This article examines the nature of the invention in intellectual property law. Taking the United States' Plant Patent Act of 1930 as its central focus, it explores the terms in which the compatibility of biological inventions with the modern paradigm of the invention was debated in the first part...

The monopoly factory: want to fix the economy? Start by fixing the Patent Office.
In 1993, Purdue Pharmaceuticals of Stamford, Conn. applied for the first in a series of patents on a drug it called Oxycontin--a painkiller to which Rush Limbaugh would later become addicted. The U.S. Patent and Trademark Office (PTO) granted those patents based on the manufacturer's contention that the drug...

Patent necessity: intellectual property dilemmas in the biotech domain & treatment equity for developing countries.
I. INTRODUCTION The dearth of access to affordable AIDS therapies in developing countries is increasingly blamed on the intellectual property norms of the North and their operationalization in global free trade regimes. This article examines key issues, interests, orientations and preferences in the North-South debate on intellectual...

ImaRx Therapeutics Names Nina Ossanna, Ph.D. Senior Director Business Development.
TUCSON, Ariz., March 5 /PRNewswire/ -- ImaRx Therapeutics, Inc. announced today that Nina Ossanna, Ph.D., is joining the growing biotechnology company as Senior Director of Business Development. Dr. Ossanna is joining ImaRx after a nine year career at The Johns Hopkins University School of Medicine, most recently...

To patent or not to patent: the European Union's new biotech directive.
I. INTRODUCTION After centuries of fusing, melting, forging, and burning inorganic materials to create useful things, we have come to a time in mankind's development when we are splicing, recombining, and transforming living material into commercial goods. Biotechnology is already used in a variety of business fields--agriculture,...

TRIPS compliance: dealing with the consequences of drug patents in India.
I. INTRODUCTION II. RESPONDING TO THE THREAT OF INCREASED DRUG PRICES A. Will Drug Prices Actually Rise? B. Drug Price Controls C. Governmental Purchasing Power D. Compulsory Licenses E. Lax Enforcement of Patent Rights F. Public-Sector Drug Development G. Summary III. RESPONDING TO THE THREAT TO INDIAN INDUSTRY A....